TVARDI THERAPEUTICS, INC. Financing Cash Flow
TVARDI THERAPEUTICS, INC. (TVRD) reported Financing Cash Flow of $22.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $1.00K, a 100.00% decline year-over-year.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$322.00K.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $24.63M, a 3469.13% increase year-over-year.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was -$1.60M.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $22.70M, a 15.91% decline from fiscal 2024.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $27.00M, a 29.23% decline from fiscal 2023.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $38.15M, a 12167.20% increase from fiscal 2022.
- TVARDI THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $311.00K, a 99.33% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$321.00K derived: sum of 2 quarters · filed 2026-03-31 | $24.31M derived: sum of 3 quarters · filed 2026-08-14 | $22.70M 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | -$322.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $24.30M derived: sum of 2 quarters · filed 2026-08-14 | $22.70M 10-Q · filed 2025-11-13 | $49.71M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | $24.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $23.02M 10-Q · filed 2026-08-14 | $50.03M derived: sum of 3 quarters · filed 2026-08-14 | $50.02M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | -$1.60M 10-Q · filed 2026-05-08 | $1.01M 10-Q · filed 2025-05-13 | $25.41M derived: sum of 2 quarters · filed 2026-05-08 | $25.39M derived: sum of 3 quarters · filed 2026-05-08 | $26.08M derived: sum of 4 quarters · filed 2026-05-08 | |||
| 2024-12-31 | $27.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $27.00M derived: sum of 2 quarters · filed 2026-03-31 | $27.68M derived: sum of 3 quarters · filed 2026-03-31 | $27.00M 10-K · filed 2026-03-31 | -$3.60M 10-K · filed 2025-03-11 | |||
| 2024-09-30 | -$14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $676.00K derived: sum of 2 quarters · filed 2025-11-13 | -$9.00K 10-Q · filed 2025-11-13 | -$1.99M 10-Q · filed 2024-11-14 | $36.47M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $690.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $5.00K 10-Q · filed 2025-08-14 | -$1.29M 10-Q · filed 2024-08-14 | $36.48M derived: sum of 3 quarters · filed 2025-08-14 | $37.60M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | -$685.00K 10-Q · filed 2025-05-13 | $35.79M derived: sum of 2 quarters · filed 2025-05-13 | $36.91M derived: sum of 3 quarters · filed 2025-05-13 | $36.91M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $36.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $37.59M derived: sum of 2 quarters · filed 2025-03-11 | $37.59M derived: sum of 3 quarters · filed 2025-03-11 | $38.15M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.12M derived: sum of 2 quarters · filed 2024-11-14 | $1.68M 10-Q · filed 2024-11-14 | $1.70M derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $560.00K 10-Q · filed 2024-08-14 | $582.00K derived: sum of 3 quarters · filed 2025-03-11 | $686.00K derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2023-03-31 | $560.00K 10-Q · filed 2024-05-13 | $582.00K derived: sum of 2 quarters · filed 2025-03-11 | $686.00K derived: sum of 3 quarters · filed 2025-03-11 | $868.00K derived: sum of 4 quarters · filed 2025-03-11 | ||||
| 2022-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $126.00K derived: sum of 2 quarters · filed 2025-03-11 | $308.00K derived: sum of 3 quarters · filed 2025-03-11 | $311.00K 10-K · filed 2025-03-11 | ||||
| 2022-09-30 | $104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $286.00K derived: sum of 2 quarters · filed 2023-11-13 | $289.00K 10-Q · filed 2023-11-13 | $45.58M derived: sum of 4 quarters · filed 2024-03-06 | ||||
| 2022-06-30 | $182.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $185.00K 10-Q · filed 2023-08-07 | $45.47M derived: sum of 3 quarters · filed 2024-03-06 | $45.81M derived: sum of 4 quarters · filed 2024-03-06 | ||||
| 2022-03-31 | $3.00K 10-Q · filed 2023-05-15 | $45.29M derived: sum of 2 quarters · filed 2024-03-06 | $45.63M derived: sum of 3 quarters · filed 2024-03-06 | $45.92M derived: sum of 4 quarters · filed 2024-03-06 | ||||
| 2021-12-31 | $45.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $45.63M derived: sum of 2 quarters · filed 2024-03-06 | $45.92M derived: sum of 3 quarters · filed 2024-03-06 | $46.61M 10-K · filed 2024-03-06 | ||||
| 2021-09-30 | $339.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $632.00K derived: sum of 2 quarters · filed 2022-11-07 | $1.32M 10-Q · filed 2022-11-07 | $39.79M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2021-06-30 | $293.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $981.00K 10-Q · filed 2022-08-08 | $39.45M derived: sum of 3 quarters · filed 2023-03-06 | $39.84M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2021-03-31 | $688.00K 10-Q · filed 2022-05-09 | $39.16M derived: sum of 2 quarters · filed 2023-03-06 | $39.55M derived: sum of 3 quarters · filed 2023-03-06 | $39.75M derived: sum of 4 quarters · filed 2023-03-06 | ||||
| 2020-12-31 | $38.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $38.86M derived: sum of 2 quarters · filed 2023-03-06 | $39.06M derived: sum of 3 quarters · filed 2023-03-06 | $39.14M 10-K · filed 2023-03-06 | ||||
| 2020-09-30 | $395.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $596.00K derived: sum of 2 quarters · filed 2021-11-08 | $671.00K 10-Q · filed 2021-11-08 | $699.00K derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-06-30 | $201.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $276.00K 10-Q · filed 2021-08-09 | $304.00K derived: sum of 3 quarters · filed 2022-03-01 | $138.67M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2020-03-31 | $75.00K 10-Q · filed 2021-05-10 | $103.00K derived: sum of 2 quarters · filed 2022-03-01 | $138.47M derived: sum of 3 quarters · filed 2022-03-01 | $142.44M derived: sum of 4 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $138.40M derived: sum of 2 quarters · filed 2022-03-01 | $142.37M derived: sum of 3 quarters · filed 2022-03-01 | $142.60M 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $138.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $142.34M derived: sum of 2 quarters · filed 2020-11-09 | $142.58M 10-Q · filed 2020-11-09 | $143.12M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | $3.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $4.21M 10-Q · filed 2020-08-10 | $4.75M derived: sum of 3 quarters · filed 2021-02-25 | $98.72M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | $234.00K 10-Q · filed 2020-05-11 | $778.00K derived: sum of 2 quarters · filed 2021-02-25 | $94.74M derived: sum of 3 quarters · filed 2021-02-25 | $110.78M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | $544.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $94.51M derived: sum of 2 quarters · filed 2021-02-25 | $110.55M derived: sum of 3 quarters · filed 2021-02-25 | $110.81M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $93.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $110.01M derived: sum of 2 quarters · filed 2019-11-05 | $110.27M 10-Q · filed 2019-11-05 | $110.45M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $16.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $16.30M 10-Q · filed 2019-08-07 | $16.49M derived: sum of 3 quarters · filed 2020-02-27 | $16.64M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $263.00K 10-Q · filed 2019-05-07 | $446.00K derived: sum of 2 quarters · filed 2020-02-27 | $597.00K derived: sum of 3 quarters · filed 2020-02-27 | |||||
| 2017-12-31 | $183.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $334.00K derived: sum of 2 quarters · filed 2020-02-27 | $87.92M 10-K · filed 2020-02-27 | |||||
| 2017-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $87.74M 10-Q · filed 2018-11-06 | ||||||
| 2017-06-30 | $87.59M 10-Q · filed 2018-08-07 | |||||||
| 2016-12-31 | $123.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |